These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27816491)

  • 1. The noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effects.
    García-Vilas JA; Pino-Ángeles A; Martínez-Poveda B; Quesada AR; Medina MÁ
    Cancer Lett; 2017 Jan; 385():1-11. PubMed ID: 27816491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.
    Dao P; Jarray R; Smith N; Lepelletier Y; Le Coq J; Lietha D; Hadj-Slimane R; Herbeuval JP; Garbay C; Raynaud F; Chen H
    Cancer Lett; 2014 Jun; 348(1-2):88-99. PubMed ID: 24657306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular disrupting activity of combretastatin analogues.
    Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
    Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells.
    Chuang CH; Liu CH; Lu TJ; Hu ML
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):310-6. PubMed ID: 25447407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway.
    Ji L; Wu M; Li Z
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30111763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo.
    Mannell H; Hellwig N; Gloe T; Plank C; Sohn HY; Groesser L; Walzog B; Pohl U; Krotz F
    J Vasc Res; 2008; 45(2):153-63. PubMed ID: 17962719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Damnacanthal, a noni anthraquinone, inhibits c-Met and is a potent antitumor compound against Hep G2 human hepatocellular carcinoma cells.
    García-Vilas JA; Quesada AR; Medina MA
    Sci Rep; 2015 Jan; 5():8021. PubMed ID: 25620570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.
    Jiang WG; Ye L; Ji K; Frewer N; Ji J; Mason MD
    Int J Oncol; 2012 Nov; 41(5):1635-42. PubMed ID: 22971748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
    Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
    Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
    Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
    J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
    Ren X; Dai M; Lin LP; Li PK; Ding J
    Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta.
    Zhong L; Guo XN; Zhang XH; Sun QM; Tong LJ; Wu ZX; Luo XM; Jiang HL; Nan FJ; Zhang XW; Lin LP; Ding J
    Cancer Biol Ther; 2006 Mar; 5(3):323-30. PubMed ID: 16575201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
    Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
    Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Damnacanthal inhibits the NF-κB/RIP-2/caspase-1 signal pathway by inhibiting p56lck tyrosine kinase.
    Kim MH; Jeong HJ
    Immunopharmacol Immunotoxicol; 2014 Oct; 36(5):355-63. PubMed ID: 25139491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
    Zhang X; Raghavan S; Ihnat M; Hamel E; Zammiello C; Bastian A; Mooberry SL; Gangjee A
    Bioorg Med Chem; 2015 May; 23(10):2408-23. PubMed ID: 25882519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities.
    Li YB; Wang ZQ; Yan X; Chen MW; Bao JL; Wu GS; Ge ZM; Zhou DM; Wang YT; Li RT
    Cancer Lett; 2013 Oct; 340(1):88-96. PubMed ID: 23856030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.